Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia
A phase 2 trial of Pacritinib in chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms, run by Theradex, now recruiting.
Overview
Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia is a phase 2 interventional study registered as NCT07033598 by Theradex, with 66 participants planned, started 2026-01-01 and due to reach its primary completion in 2028-07. Interventions recorded: Pacritinib and Hydroxyurea.
Similar pages
not linked directly; found by shared links- TrialPhase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TrialA Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TrialStudy to Evaluate the Safety and Tolerability of EP0042
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TrialA Study to Assess Safety, Tolerability and Preliminary Efficacy of Bexmarilimab in Combination With Standard of Care in Patients With Hematological Malignancies
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TrialClinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TreatmentJBI-802
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TreatmentBexmarilimab
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.
- TreatmentTuspetinib
Shares Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms and the tag pipeline.